O	0	13	Sensitization	Sensitization	NN	B-NP
O	14	16	to	to	TO	B-PP
O	17	26	gimatecan	gimatecan	NN	B-NP
O	26	27	-	-	HYPH	B-NP
O	27	34	induced	induce	VBN	I-NP
O	35	44	apoptosis	apoptosis	NN	I-NP
O	45	47	by	by	IN	B-PP
O	48	53	tumor	tumor	NN	B-NP
O	54	62	necrosis	necrosis	NN	I-NP
O	63	69	factor	factor	NN	I-NP
O	69	70	-	-	HYPH	B-NP
O	70	77	related	relate	VBN	I-NP
O	78	87	apoptosis	apoptosis	NN	I-NP
O	88	96	inducing	induce	VBG	I-NP
O	97	103	ligand	ligand	NN	I-NP
O	104	106	in	in	IN	B-PP
B-Cell	107	115	prostate	prostate	NN	B-NP
I-Cell	116	125	carcinoma	carcinoma	NN	I-NP
I-Cell	126	131	cells	cell	NNS	I-NP
O	131	132	.	.	.	O

O	134	139	Since	Since	IN	B-SBAR
O	140	143	the	the	DT	B-NP
O	144	153	intrinsic	intrinsic	JJ	I-NP
O	154	164	resistance	resistance	NN	I-NP
O	165	167	of	of	IN	B-PP
B-Cancer	168	176	prostate	prostate	NN	B-NP
I-Cancer	177	186	carcinoma	carcinoma	NN	I-NP
O	187	193	likely	likely	RB	B-ADVP
O	194	202	reflects	reflect	VBZ	B-VP
O	203	204	a	a	DT	B-NP
O	205	208	low	low	JJ	I-NP
O	209	223	susceptibility	susceptibility	NN	I-NP
O	224	226	to	to	TO	B-PP
O	227	231	drug	drug	NN	B-NP
O	231	232	-	-	HYPH	B-NP
O	232	239	induced	induce	VBN	I-NP
O	240	249	apoptosis	apoptosis	NN	I-NP
O	249	250	,	,	,	O
O	251	253	in	in	IN	B-PP
O	254	258	this	this	DT	B-NP
O	259	264	study	study	NN	I-NP
O	265	267	we	we	PRP	B-NP
O	268	276	explored	explore	VBD	B-VP
O	277	280	the	the	DT	B-NP
O	281	292	possibility	possibility	NN	I-NP
O	293	295	of	of	IN	B-PP
O	296	307	sensitizing	sensitize	VBG	B-VP
B-Cell	308	316	prostate	prostate	NN	B-NP
I-Cell	317	326	carcinoma	carcinoma	NN	I-NP
I-Cell	327	332	cells	cell	NNS	I-NP
O	333	335	to	to	TO	B-PP
O	336	345	apoptosis	apoptosis	NN	B-NP
O	346	348	by	by	IN	B-PP
O	349	360	combination	combination	NN	B-NP
O	361	363	of	of	IN	B-PP
O	364	369	TRAIL	TRAIL	NN	B-NP
O	370	374	with	with	IN	B-PP
O	375	388	camptothecins	camptothecin	NNS	B-NP
O	388	389	.	.	.	O

O	390	396	Indeed	Indeed	RB	B-ADVP
O	396	397	,	,	,	O
O	398	403	these	these	DT	B-NP
O	404	410	agents	agent	NNS	I-NP
O	411	414	are	be	VBP	B-VP
O	415	420	known	know	VBN	I-VP
O	421	423	to	to	TO	I-VP
O	424	432	activate	activate	VB	I-VP
O	433	442	different	different	JJ	B-NP
O	443	451	pathways	pathway	NNS	I-NP
O	452	454	of	of	IN	B-PP
O	455	464	apoptosis	apoptosis	NN	B-NP
O	464	465	.	.	.	O

O	466	475	Topotecan	Topotecan	NN	B-NP
O	475	476	-	-	HYPH	O
O	477	480	and	and	CC	O
O	481	490	gimatecan	gimatecan	NN	B-NP
O	491	498	induced	induce	VBD	B-VP
O	499	507	moderate	moderate	JJ	B-ADJP
O	508	510	up	up	RB	B-ADVP
O	510	511	-	-	HYPH	O
O	511	521	regulation	regulation	NN	B-NP
O	522	524	of	of	IN	B-PP
O	525	530	TRAIL	TRAIL	NN	B-NP
O	530	531	-	-	HYPH	B-NP
O	531	533	R1	R1	NN	I-NP
O	534	537	and	and	CC	O
O	538	539	-	-	HYPH	B-NP
O	539	541	R2	R2	NN	I-NP
O	542	547	which	which	WDT	B-NP
O	548	556	resulted	result	VBD	B-VP
O	557	559	in	in	IN	B-PP
O	560	561	a	a	DT	B-NP
O	562	571	different	different	JJ	I-NP
B-Cell	572	576	cell	cell	NN	I-NP
O	577	585	response	response	NN	I-NP
O	586	588	to	to	TO	B-PP
O	589	592	the	the	DT	B-NP
O	593	604	combination	combination	NN	I-NP
O	605	607	in	in	IN	B-PP
O	608	616	androgen	androgen	NN	B-NP
O	616	617	-	-	HYPH	B-NP
O	617	628	independent	independent	JJ	I-NP
B-Cell	629	634	cells	cell	NNS	I-NP
O	635	636	(	(	(	O
B-Cell	636	638	DU	DU	NN	B-NP
I-Cell	638	639	-	-	HYPH	B-NP
I-Cell	639	642	145	145	CD	I-NP
O	643	646	and	and	CC	I-NP
B-Cell	647	649	PC	PC	NN	I-NP
I-Cell	649	650	-	-	HYPH	B-NP
I-Cell	650	651	3	3	CD	I-NP
O	651	652	)	)	)	O
O	652	653	.	.	.	O

O	654	656	In	In	IN	B-PP
B-Cell	657	659	DU	DU	NN	B-NP
I-Cell	659	660	-	-	HYPH	B-NP
I-Cell	660	663	145	145	CD	I-NP
I-Cell	664	669	cells	cell	NNS	I-NP
O	670	679	apoptosis	apoptosis	NN	I-NP
O	680	683	was	be	VBD	B-VP
O	684	693	increased	increase	VBN	I-VP
O	694	696	by	by	IN	B-PP
O	697	702	lower	low	JJR	B-NP
O	703	708	TRAIL	TRAIL	NN	I-NP
O	709	723	concentrations	concentration	NNS	I-NP
O	724	727	and	and	CC	O
O	728	731	was	be	VBD	B-VP
O	732	739	earlier	earlier	RBR	B-ADJP
O	740	744	than	than	IN	B-PP
O	745	747	in	in	IN	B-PP
B-Cell	748	750	PC	PC	NN	B-NP
I-Cell	750	751	-	-	HYPH	B-NP
I-Cell	751	752	3	3	CD	I-NP
I-Cell	753	758	cells	cell	NNS	I-NP
O	758	759	,	,	,	O
O	760	762	as	as	IN	B-SBAR
O	763	768	shown	show	VBN	B-VP
O	769	774	using	use	VBG	B-VP
O	775	782	Annexin	Annexin	NN	B-NP
O	783	784	V	V	NN	I-NP
O	784	785	-	-	HYPH	O
O	785	792	binding	bind	VBG	B-NP
O	793	798	assay	assay	NN	I-NP
O	798	799	.	.	.	O

O	800	803	The	The	DT	B-NP
O	804	812	relative	relative	JJ	I-NP
O	813	823	resistance	resistance	NN	I-NP
O	824	826	of	of	IN	B-PP
B-Cell	827	829	PC	PC	NN	B-NP
I-Cell	829	830	-	-	HYPH	B-NP
I-Cell	830	831	3	3	CD	I-NP
I-Cell	832	837	cells	cell	NNS	I-NP
O	838	840	to	to	TO	B-PP
O	841	845	drug	drug	NN	B-NP
O	845	846	-	-	HYPH	B-NP
O	846	853	induced	induce	VBN	I-NP
O	854	863	apoptosis	apoptosis	NN	I-NP
O	864	867	was	be	VBD	B-VP
O	868	878	associated	associate	VBN	I-VP
O	879	883	with	with	IN	B-PP
O	884	896	constitutive	constitutive	JJ	B-NP
O	897	900	Akt	Akt	NN	I-NP
O	901	911	activation	activation	NN	I-NP
O	911	912	,	,	,	O
O	913	919	higher	high	JJR	B-NP
O	920	926	levels	level	NNS	I-NP
O	927	929	of	of	IN	B-PP
O	930	935	cFLIP	cFLIP	NN	B-NP
O	935	936	-	-	HYPH	B-NP
O	936	937	L	L	NN	I-NP
O	938	941	and	and	CC	I-NP
O	942	945	Bcl	Bcl	NN	I-NP
O	945	946	-	-	HYPH	O
O	946	947	2	2	CD	B-NP
O	947	948	,	,	,	O
O	949	952	and	and	CC	O
O	953	958	lower	low	JJR	B-NP
O	959	965	levels	level	NNS	I-NP
O	966	968	of	of	IN	B-PP
O	969	972	Bax	Bax	NN	B-NP
O	972	973	.	.	.	O

O	974	977	The	The	DT	B-NP
O	978	987	different	different	JJ	I-NP
O	988	998	expression	expression	NN	I-NP
O	998	999	/	/	SYM	B-NP
O	999	1009	activation	activation	NN	B-NP
O	1010	1012	of	of	IN	B-PP
O	1013	1022	apoptosis	apoptosis	NN	B-NP
O	1022	1023	-	-	HYPH	O
O	1023	1030	related	relate	VBN	B-NP
O	1031	1038	factors	factor	NNS	I-NP
O	1039	1046	appears	appear	VBZ	B-VP
O	1047	1049	to	to	TO	I-VP
O	1050	1059	influence	influence	VB	I-VP
O	1060	1063	the	the	DT	B-NP
O	1064	1077	sensitization	sensitization	NN	I-NP
O	1078	1080	of	of	IN	B-PP
B-Cell	1081	1089	prostate	prostate	NN	B-NP
I-Cell	1090	1099	carcinoma	carcinoma	NN	I-NP
I-Cell	1100	1105	cells	cell	NNS	I-NP
O	1106	1108	by	by	IN	B-PP
O	1109	1114	TRAIL	TRAIL	NN	B-NP
O	1114	1115	.	.	.	O

O	1116	1128	Potentiation	Potentiation	NN	B-NP
O	1129	1131	of	of	IN	B-PP
O	1132	1144	camptothecin	camptothecin	NN	B-NP
O	1144	1145	-	-	HYPH	B-NP
O	1145	1152	induced	induce	VBN	I-NP
O	1153	1162	apoptosis	apoptosis	NN	I-NP
O	1163	1165	by	by	IN	B-PP
O	1166	1171	TRAIL	TRAIL	NN	B-NP
O	1172	1179	appears	appear	VBZ	B-VP
O	1180	1189	dependent	dependent	JJ	B-ADJP
O	1190	1192	on	on	IN	B-PP
O	1193	1204	cooperation	cooperation	NN	B-NP
O	1205	1212	between	between	IN	B-PP
O	1213	1222	extrinsic	extrinsic	JJ	B-NP
O	1223	1226	and	and	CC	I-NP
O	1227	1236	intrinsic	intrinsic	JJ	I-NP
O	1237	1245	pathways	pathway	NNS	I-NP
O	1245	1246	,	,	,	O
O	1247	1249	as	as	IN	B-SBAR
O	1250	1260	documented	document	VBN	B-VP
O	1261	1263	by	by	IN	B-PP
O	1264	1268	loss	loss	NN	B-NP
O	1269	1271	of	of	IN	B-PP
O	1272	1275	the	the	DT	B-NP
O	1276	1289	sensitization	sensitization	NN	I-NP
O	1290	1292	to	to	TO	B-PP
O	1293	1302	apoptosis	apoptosis	NN	B-NP
O	1303	1312	following	follow	VBG	B-PP
O	1313	1322	reduction	reduction	NN	B-NP
O	1323	1325	of	of	IN	B-PP
O	1326	1333	caspase	caspase	NN	B-NP
O	1334	1335	8	8	CD	I-NP
O	1336	1341	after	after	IN	B-PP
O	1342	1347	small	small	JJ	B-NP
O	1348	1359	interfering	interfere	VBG	I-NP
O	1360	1363	RNA	RNA	NN	I-NP
O	1364	1376	transfection	transfection	NN	I-NP
O	1376	1377	.	.	.	O

O	1378	1381	The	The	DT	B-NP
O	1382	1390	efficacy	efficacy	NN	I-NP
O	1391	1393	of	of	IN	B-PP
O	1394	1397	the	the	DT	B-NP
O	1398	1406	approach	approach	NN	I-NP
O	1407	1410	may	may	MD	B-VP
O	1411	1413	be	be	VB	I-VP
O	1414	1424	critically	critically	RB	B-ADJP
O	1425	1434	dependent	dependent	JJ	I-ADJP
O	1435	1437	on	on	IN	B-PP
O	1438	1441	the	the	DT	B-NP
O	1442	1451	intrinsic	intrinsic	JJ	I-NP
O	1452	1466	susceptibility	susceptibility	NN	I-NP
O	1467	1469	to	to	TO	B-PP
O	1470	1479	apoptosis	apoptosis	NN	B-NP
O	1480	1482	of	of	IN	B-PP
O	1483	1492	different	different	JJ	B-NP
B-Cancer	1493	1499	tumors	tumor	NNS	I-NP
O	1499	1500	.	.	.	O

O	1501	1506	These	These	DT	B-NP
O	1507	1519	observations	observation	NNS	I-NP
O	1520	1527	support	support	VBP	B-VP
O	1528	1532	that	that	IN	B-SBAR
O	1533	1536	the	the	DT	B-NP
O	1537	1547	activation	activation	NN	I-NP
O	1548	1550	of	of	IN	B-PP
O	1551	1559	multiple	multiple	JJ	B-NP
O	1560	1567	signals	signal	NNS	I-NP
O	1568	1573	could	could	MD	B-VP
O	1574	1581	enhance	enhance	VB	I-VP
O	1582	1591	apoptotic	apoptotic	JJ	B-NP
O	1592	1600	response	response	NN	I-NP
O	1601	1604	and	and	CC	O
O	1605	1612	suggest	suggest	VBP	B-VP
O	1613	1616	the	the	DT	B-NP
O	1617	1628	therapeutic	therapeutic	JJ	I-NP
O	1629	1637	interest	interest	NN	I-NP
O	1638	1640	of	of	IN	B-PP
O	1641	1644	the	the	DT	B-NP
O	1645	1650	TRAIL	TRAIL	NN	I-NP
O	1650	1651	/	/	SYM	B-NP
O	1651	1663	camptothecin	camptothecin	NN	I-NP
O	1664	1675	combination	combination	NN	I-NP
O	1675	1676	.	.	.	O

